Senators Ask FDA to Review New Mifepristone Safety Claims; Commissioner Pledges to Examine Data

Senator Cindy Hyde‑Smith and others asked whether the FDA would review a recently released analysis alleging increased serious adverse events related to mifepristone and whether the agency would consider restoring earlier safety conditions.

Senator Hyde‑Smith summarized the report's topline finding as saying that "10.93 percent of women experience sepsis infection, hemorrhaging or other serious adverse events within 45 days following the chemical abortion," and asked whether that finding would prompt a return to prior safeguards such as an in‑person physician visit or REMS‑style restrictions.

Dr. McCary responded that he had seen the topline results referenced in committee and that the agency would "take a hard look at" the data when the underlying dataset and methodology become available. He noted that, to date, he had not seen a peer‑reviewed publication or the underlying dataset for that analysis and said the FDA would review it if provided.

Why it matters: Committees and the public rely on FDA assessments to determine whether post‑market data require regulatory action. Senators pressed for clarity because the cited analysis, if verifiable, could predict changes to access and clinical practice.

What was not decided: The FDA made no immediate changes to mifepristone policy at the hearing and did not reinstate prior safety requirements. Dr. McCary said the agency would examine the data once it becomes available and did not pre‑commit to any particular regulatory outcome.

Ending: Senators said they would submit follow‑up questions and expected the agency to provide a data‑driven response.